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Triple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump
inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication
rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To
determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change
the response to therapy.
Methods: Two hundred patients with peptic ulcer (upper endoscopy) and H. pylori infection
(histology and rapid urease test — RUT) were included. A proton pump inhibitor (lansoprazole 30 mg or omeprazole 20 mg),
tinidazole 500 mg, and clarithromycin 250 mg were dispensed twice a day for a seven-day period. Eradication was assessed after 10
to 12 weeks of treatment through histology and RUT.
Results: The eradication rate of H. pylori per protocol was 65% (128/196 patients). This rate was 53% for previously treated
patients, rising to 76% for not previously treated patients, with a statistical difference p<0.01. No significant difference was observed
regarding sex, tobacco use, alcohol consumption, and NSAID use, but for elderly patients the difference was p = 0.05. Adherence to
treatment was good, and side effects were mild.
Conclusions: A proton pump inhibitor, tinidazole, and clarithromycin bid for seven days resulted in H. pylori eradication in
65% of the patients. Previous treatments were the main cause of treatment failure.
DESCRIPTORS: Peptic Ulcer Treatment. Helicobacter pylori Eradication. Proton pump inhibitor. Tinidazole.
Clarithromycin.
The identification of H. pylori in the
gastric epithelium and its relationship
with peptic disease1 resulted in a re-
markable change in the management of
peptic ulcers. It is a worldwide consen-
sus that eradication of the bacterium is
the corner stone of peptic ulcer cure2,3.
The low rates of eradication observed in
mono therapies and double therapies
have encouraged the use of three anti-
biotics or two antibiotics and a proton
pump inhibitor4,5,6 Efficacy, the short
period of treatment, low doses, few side
effects, and low cost, make triple
therapy with a proton pump inhibitor,
macrolide, and nitroimidazole a very
acceptable treatment for H. pylori eradi-
cation7,8,9. In Brazil, as well as in all de-
veloping countries, the risk of a thera-
peutic failure because of H. pylori
strains that are resistant to metronida-
zole has to be considered7, because of
its worldwide use. The aim of our study
was to observe the eradication rate of H.
pylori in a Brazilian peptic ulcer popu-
lation under this treatment. The influ-
ence of previous treatments, gender,
age, tobacco, alcohol, and NSAID use
on therapy was evaluated.

REV. HOSP. CLÍN. FAC. MED. S. PAULO 56(1):11-16, 2001 JANUARY-FEBRUARY
PATIENTS AND METHOD
Two hundred outpatients seen from
December 1995 to September 1996
were invited to participate. Inclusion
criteria: 1. Patients with gastric or
duodenal peptic ulcer (active or
healed). 2. H pylori infection diag-
nosed by both histology and RUT. 3.
Patients with no previous treatment and
previously treated with bismuth
subcitrate, metronidazole, and
amoxicillin or tetracycline. Exclusion
criteria: 1. Patients under 16 years of
age. 2. Previous use of antibiotic
therapy at least three months prior to
the inclusion. 3. Pregnant or lactating
women. 4. Prior gastric surgery. 5. Pa-
tients with any decompensated disease.
The Ethical and Scientific Commit-
tee of Hospital das Clinicas approved
this protocol. Before inclusion, all par-
ticipants signed a post-informed con-
sent statement.
Patients’ data were obtained from
standard questionnaires conducted at
patients’ inclusion in the study.
H. pylori infection was confirmed
by histological examination (H&E and
Giemsa methods) and rapid urease test
(RUT) performed on biopsy material
taken during upper endoscopy (2
samples of antrum and 2 samples of
gastric body). H. pylori was considered
eradicated when the RUT and histo-
logical examination performed 10 to
12 weeks after the end of the treatment
were negative.
Clarithromycin 250 mg plus
tinidazole 500 mg and a proton pump
inhibitor (lansoprazole 30 mg or
omeprazole 20 mg) were dispensed
twice a day for a seven-day period. Af-
ter treatment, compliance was assessed
by pill consumption. Patients were
asked about adverse effects. Patients
were requested to stop all medications
except antacids if needed for dyspep-
tic symptom relief or other medications
for chronic use in concomitant dis-
eases.
Statistical analysis was performed
with software package SPSS v.3.0
(SPSS Inc., USA). The variables, gen-
der, age, previous treatment, tobacco,
alcohol, and NSAIDs were analyzed
by the chi-square method. A p value <
0.05 was taken as being significant. A
multiple logistic regression analysis
was also performed; eradication was
the dependent variable, and gender,
age, previous treatment, tobacco,  al-
cohol, and NSAIDs were the indepen-
dent variables.
RESULTS
Two hundred patients were in-
cluded in the study. There were 196
patients available for analysis “per pro-
tocol”, most of them female with mean
age = 44 (range = 16 to 80). The de-
mographic data are shown in table 1.
Side effects were observed in 36
patients (18%), usually mild ones. One
patient had to stop medication because
of severe nausea and vomiting. Taste
alterations, nausea, diarrhea, and diz-
ziness were the most frequent side ef-
fects observed. One patient reported
glossitis and vulvae pruritus.
Patients’ adherence was high. All
except 3 patients took more than 90%
of the pills.
H. pylori was eradicated in 128 of
196 (65%) patients (Table 2). Therapy
efficacy depended on the previous
treatment. For patients previously
treated, eradication percentage was
53% (49/92), rising to 76% (79/104)
for untreated patients, a statistically
significant difference (p< 0.01). Eradi-
cation rate was different in males: 71%
(53/75) when compared to females:
62% (75/121), without a statistical dif-
ference  (p = 0.21). Eradication was
not affected by the use of tobacco
(61% x 67%), alcohol (63% x 72%),
or NSAIDs (69% x 64%). The rate for
patients over 44 years: 73% (62/85)
was higher than for those under 44:
60% (66/111), with p value = 0.05
(Table 3).
Table 1 - Clinical data.
Age over 44 44% (87/200)
Female 62% (123/200)
Previous treatment 47% (93/200)
Smokers 36% (70/195*)
NSAID Users 16% (32/198*)
Alcohol Users 15% (29/193*)
* missing data
Table 2 - Eradication rates.
% (n) CI (95%)
Intention to treat 64% (128/200) 57% - 70%
“Per protocol” 65% (128/196) 58% - 72%
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DISCUSSION
The objective of H. pylori-depen-
dent peptic ulcer treatment should be
healing the ulcer and eradication of the
bacteria. Many treatment schedules
have been suggested to eradicate H. py-
lori 6,10,11. Eradication success depends
mainly on adherence to treatment and
bacterial resistance to medications12-15.
There is no doubt that the ideal treat-
ment must be effective at a low cost,
besides being simple and free of side
effects. It is a consensus in developed
countries that an acceptable eradication
rate is 90% or more2,9,11,16. Triple
therapy with a proton pump inhibitor
was considered the treatment of choice
to eradicate H. pylori2,3,17-23. Association
of a proton pump inhibitor plus
amoxicillin or nitroimidazole and
clarithromycin results in an eradication
rate higher than 90% 6,8,11,17,18,20-22. In
populations where resistance to met-
ronidazole is more than 30%, low ef-
fectiveness has been reported13,14. In
Brazil, H. pylori resistance to metron-
idazole is over 30%7, so it was not sur-
prising that the 90% success rate in
eradication was not reached by our
population24-27. In our study, the com-
pliance to treatment was good; all ex-
cept 3 patients took more than 90% of
the pills. Although we do not have data
on bacteria sensitivity, the 76% eradi-
cation rate observed in the first treated
patients was probably due to tinidazole
resistance. Similarly, a greater propor-
tion of metronidazole-resistant strains
present in patients underwent treatment
for the second time, could explain the
low 53% eradication rate observed.
Moshkowitz28 obtained similar data.
These results reinforce that it is pref-
erable that nitroimidazoles not be used
in triple therapy schedules in Brazil.
Macheda and Zaterka (unpublished re-
sults) and Chehter et al.29 obtained 85%
eradication in patients undergoing 7-
day treatment with lansoprazole 30 mg
plus amoxicillin 1.0 g and
clarithromycin 0.5 g bid. They show
that the use of amoxicillin instead of
tinidazole increases the eradication
rate, which is similar to the results ob-
served in developed countries. Side ef-
fects were reported by 18% of our pa-
tients, usually mild ones, therefore not
interfering with adherence to treatment.
Only one patient with persistent nau-
sea and vomiting resulted in with-
drawal from treatment. As observed by
other investigators, we expected to find
a higher eradication rate in males, since
women would theoretically have been
exposed to treatment with
nitroimidazoles30,31 more often, and
consequently would show a higher re-
sistance to tinidazole. However, the
eradication rate was similar in males
and females. It is possible that males
and females are equally exposed to the
previous use of nitroimidazole in Bra-
zil7.
In a recent work32, smoking was a
predictive factor of treatment failure,
but our study failed to confirm this, in
agreement with the Kadayifçi report33.
Alcohol and NSAID use did not in-
fluence the outcome of eradication
therapy.
There was a predominance of
women in our study, which is a rule in
all outpatient services in Brazil34. We
cannot rule out an increase in female
prevalence of peptic ulcer as partially
responsible for the increased number
of women in our study. An increased
incidence of women with peptic ulcer
disease has been reported in the USA
since 198035,36. The better eradication
rate of therapy for patients over 44
years old is difficult to explain. Simi-
larly, Cutler and Schubert27and
Labens37 also observed this response in
elderly patients. Nevertheless,
Moayyedi31 did not find any influence
of age on eradication rate using a treat-
ment schedule similar to ours.
Table 3 - “Per Protocol” eradication rates.
Variable Attribute p
Tobacco users non-users
61% 67% 0.42
(42/69) (82/123)
Alcohol users non-users
72% 63% 0.27
(21/29) (102/161)
NSAID users non-users
69% 64% 0.63
(22/32) (105/163)
Gender male female
71% 62% 0.21
(53/75) (75/121)
Age (yrs) <44 44
60% 73% 0.05
(66/111) (62/85)
Previous treatment with without
53% 76% <0.01
(49/92) (79/104)
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RESUMO RHCFAP/3030
SILVA FM e col. - Fatores que
afetam a erradicação do Helicobacter
pylori usando um tratamento triplo de
sete dias com um inibidor de bomba de
prótons associado ao tinidazol e a
claritromicina, em pacientes brasileiros
com úlcera péptica. Rev. Hosp. Clín.
Fac. Med. S. Paulo 56(1):11-16, 2001.
O esquema tríplice tem sido de-
monstrado como sendo o melhor tra-
tamento para a erradicação do
Helicobacter pylori. Nos países indus-
trializados o uso de um inibidor de
bomba de prótons associado a
claritromicina e a amoxicilina ou a um
nitroimidazólico, tem proporcionado os
melhores resultados. Objetivamos estu-
dar na nossa população a taxa de
erradicação do H. pylori para a asso-
ciação de um inibidor de bomba de
prótons com o tinidazol e a clari-
tromicina e determinar se a resposta ao
tratamento é influenciada pelo trata-
mento prévio, sexo, tabagismo, alco-
olismo, idade e uso de anti-inflamató-
rios não esteroidais (AINEs).
Pacientes e procedimentos: Duzen-
tos pacientes com diagnóstico endos-
cópico de úlcera péptica e com infecção
pelo H. pylori, confirmada pelo exame
histológico e pelo teste rápido da urease
(TRU), foram incluídos no estudo. Um
inibidor de bomba de prótons
(lansoprazol 30mg ou omeprazol 20
mg), tinidazol 500mg e claritromicina
250mg foram ministrados duas vezes ao
dia, por um período de 7 dias. A
erradicação era determinada depois de
10 a 12 semanas após o fim do trata-
mento, por histologia e TRU.
Resultados: O percentual de erradi-
cação do H. pylori (por protocolo) foi de
65% (128/196 pacientes). Para pacientes
previamente tratados o valor foi de 53%,
aumentando para 76% nos pacientes não
previamente tratados com diferença es-
tatística (p<0,01). Não houve diferença
significativa para sexo, tabagismo, alco-
olismo e uso de AINEs, mas para paci-
entes de mais idade houve diferença com
p = 0,05. A aderência ao tratamento foi
boa e os efeitos adversos, leves.
Conclusão: O esquema inibidor de
bomba de prótons, tinidazol e claritro-
micina, dados duas vezes ao dia por 7
dias proporcionou erradicação do H.
pylori em 65% dos pacientes. O trata-
mento prévio foi o principal fator para
seu insucesso.
DESCRITORES: Tratamento da
úlcera péptica. Erradicação do
Helicobacter pylori. Inibidor de
bomba de prótons.  Tinidazol.
Claritromicina.
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